These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35086953)

  • 1. HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models.
    Gómez V; Galazi M; Weitsman G; Monypenny J; Al-Salemee F; Barber PR; Ng K; Beatson R; Szokol B; Orfi L; Mullen G; Vanhaesebroeck B; Chowdhury S; Leung HY; Ng T
    Mol Cancer Ther; 2022 Apr; 21(4):667-676. PubMed ID: 35086953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
    Pungsrinont T; Kallenbach J; Baniahmad A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
    Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
    Choudhury AD
    Prostate; 2022 Aug; 82 Suppl 1():S60-S72. PubMed ID: 35657152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling.
    Ding X; Xu X; He XF; Yuan Y; Chen C; Shen XY; Su S; Chen Z; Xu ST; Huang YH
    Bioengineered; 2021 Dec; 12(1):803-814. PubMed ID: 33648424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
    Tan M; Xu J; Siddiqui J; Feng F; Sun Y
    Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
    Shorning BY; Dass MS; Smalley MJ; Pearson HB
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.
    Raith F; O'Donovan DH; Lemos C; Politz O; Haendler B
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
    Seront E; Pinto A; Bouzin C; Bertrand L; Machiels JP; Feron O
    Br J Cancer; 2013 Sep; 109(6):1586-92. PubMed ID: 23989949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
    Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S
    Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
    Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
    Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
    Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines.
    Lim HJ; Wang X; Crowe P; Goldstein D; Yang JL
    Anticancer Res; 2016 Nov; 36(11):5765-5771. PubMed ID: 27793898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
    Le B; Powers GL; Tam YT; Schumacher N; Malinowski RL; Steinke L; Kwon G; Marker PC
    PLoS One; 2017; 12(3):e0174658. PubMed ID: 28350865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.
    Gravina GL; Mancini A; Scarsella L; Colapietro A; Jitariuc A; Vitale F; Marampon F; Ricevuto E; Festuccia C
    Tumour Biol; 2016 Jan; 37(1):341-51. PubMed ID: 26219891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
    Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
    Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
    Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN.
    Park S; Zhao D; Hatanpaa KJ; Mickey BE; Saha D; Boothman DA; Story MD; Wong ET; Burma S; Georgescu MM; Rangnekar VM; Chauncey SS; Habib AA
    Cancer Res; 2009 May; 69(10):4107-11. PubMed ID: 19435890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.